Biotech | May 12, 2022
Mawi DNA Technologies launches NextSWAB for Covid-19 test results
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
The company also raised Rs 270 crore investment from Temasek in 2019
Cipla has reported consolidated financial results for the period ended March 31, 2022
Subscribe To Our Newsletter & Stay Updated
